Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000059478-26-000072
Filing Date
2026-07-30
Accepted
2026-07-30 16:39:26
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 12375
2 schedulea.pdf EX-99 122152
  Complete submission text file 0000059478-26-000072.txt   182653
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filed by) CIK: 0000059478 (see all company filings)

EIN.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: SCHEDULE 13D
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1150 MARINA VILLAGE PKWY ALAMEDA CA 94501
Business Address 1150 MARINA VILLAGE PKWY ALAMEDA CA 94501 510-454-0213
Scribe Therapeutics, Inc. (Subject) CIK: 0001853921 (see all company filings)

EIN.: 822157847 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95831 | Film No.: 261223988
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)